Cargando…

Long-Term Cardiovascular and Cerebrovascular Challenges Posed by COVID-19 in Patients With Familial Hypercholesterolemia

Detalles Bibliográficos
Autores principales:	Vuorio, Alpo, Raal, Frederick, Ijäs, Petra, Kaste, Markku, Kovanen, Petri T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131188/ https://www.ncbi.nlm.nih.gov/pubmed/35645833 http://dx.doi.org/10.3389/fphar.2022.890141

Ejemplares similares

Familial hypercholesterolemia and statins in the COVID-19 era: Mitigating the risk of ischemic stroke
por: Vuorio, Alpo, et al.
Publicado: (2021)

Prevention of Cardiovascular Burden in COVID-19 Patients Suffering from Familial Hypercholesterolemia: A Global Challenge
por: Vuorio, Alpo, et al.
Publicado: (2021)

Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment
por: Vuorio, Alpo, et al.
Publicado: (2021)

Hospitalized Children With Familial Hypercholesterolemia and COVID-19: A Case for Preventive Anticoagulation
por: Vuorio, Alpo, et al.
Publicado: (2021)

Opportunities for preventing further endothelial dysfunction in pregnant COVID-19 patients with familial hypercholesterolemia
por: Vuorio, Alpo, et al.
Publicado: (2022)

Patients with familial hypercholesterolemia and COVID-19: Efficient and ongoing cholesterol lowering is paramount for the prevention of acute myocardial infarction
por: Kovanen, Petri T., et al.
Publicado: (2021)

Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2021)

Cholesterol-lowering drugs for high-risk hypercholesterolemia patients with COVID-19 while on Paxlovid™ therapy
por: Vuorio, Alpo, et al.
Publicado: (2022)

Coronary microcirculatory dysfunction in hypercholesterolemic patients with COVID-19: potential benefit from cholesterol-lowering treatment
por: Vuorio, Alpo, et al.
Publicado: (2023)

Familial hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition
por: Vuorio, Alpo, et al.
Publicado: (2021)

Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia
por: Vuorio, Alpo, et al.
Publicado: (2020)

Elevated Lipoprotein(a) and Cerebral Venous Sinus Thrombosis in COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2021)

Decreasing the Cholesterol Burden in Heterozygous Familial Hypercholesterolemia Children by Dietary Plant Stanol Esters
por: Vuorio, Alpo, et al.
Publicado: (2018)

Wildfire smoke exposure and cardiovascular disease—should statins be recommended to prevent cardiovascular events?
por: Vuorio, Alpo, et al.
Publicado: (2023)

Monkeypox is a global public health emergency: The role of repurposing cholesterol lowering drugs not to be forgotten
por: Vuorio, Alpo, et al.
Publicado: (2022)

Drug-drug interaction with oral antivirals for the early treatment of COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2023)

Statins as Adjuvant Therapy for COVID-19 to Calm the Stormy Immunothrombosis and Beyond
por: Vuorio, Alpo, et al.
Publicado: (2021)

Inhibition of hepatic microsomal triglyceride transfer protein – a novel therapeutic option for treatment of homozygous familial hypercholesterolemia
por: Vuorio, Alpo, et al.
Publicado: (2014)

Hypercholesterolemia and COVID-19: Statins for Lowering the Risk of Venous Thromboembolism
por: Vuorio, Alpo, et al.
Publicado: (2021)

Continuation of fibrate therapy in patients with metabolic syndrome and COVID-19: a beneficial regime worth pursuing
por: Vuorio, Alpo, et al.
Publicado: (2022)

SARS-CoV-2 reinfection: Adding insult to dysfunctional endothelium in patients with atherosclerotic cardiovascular disease
por: Kovanen, Petri T., et al.
Publicado: (2023)

Mucormycosis and glucose‐regulated protein 78 in COVID‐19: Amenable to statin treatment?
por: Vuorio, Alpo, et al.
Publicado: (2021)

Comment on: “Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry”
por: Vuorio, Alpo, et al.
Publicado: (2021)

Editorial: Genetics of Familial Hypercholesterolemia: New Insight
por: Vuorio, Alpo, et al.
Publicado: (2021)

Editorial: Genetics of familial hypercholesterolemia: New insight—Volume II
por: Vuorio, Alpo, et al.
Publicado: (2022)

Compliance of the aorta in two diseases affecting vascular elasticity, familial hypercholesterolemia and diabetes: a MRI study
por: Soljanlahti, Sami, et al.
Publicado: (2008)

Aorta of young and middle-aged heterozygous familial hypercholesterolemia patients shows no functional or morphological impairment assessed by MRI
por: Soljanlahti, Sami, et al.
Publicado: (2008)

Self-Harm in Aviation Medicine—A Complex Challenge During a Pandemic
por: Vuorio, Alpo, et al.
Publicado: (2021)

Gene expression differences between stroke-associated and asymptomatic carotid plaques
por: Saksi, Jani, et al.
Publicado: (2011)

Familial Hypercholesterolemia: New Horizons for Diagnosis and Effective Management
por: Mytilinaiou, Maria, et al.
Publicado: (2018)

Editorial: The Challenge Posed by New Synthetic Opioids: Pharmacology and Toxicology
por: Pichini, Simona, et al.
Publicado: (2019)

Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High‐Dose Statin Therapy
por: Raal, Frederick, et al.
Publicado: (2013)

Chinese herbal injection for cardio-cerebrovascular disease: Overview and challenges
por: Huajuan, Jiang, et al.
Publicado: (2023)

An LDLR missense variant poses high risk of familial hypercholesterolemia in 30% of Greenlanders and offers potential of early cardiovascular disease intervention
por: Jørsboe, Emil, et al.
Publicado: (2022)

Retrospective analysis of cohort database: Phenotypic variability in a large dataset of patients confirmed to have homozygous familial hypercholesterolemia
por: Raal, Frederick J., et al.
Publicado: (2016)

Risk of Recurrent Coronary Events in Patients With Familial Hypercholesterolemia; A 10-Years Prospective Study
por: Arnesen, Kjell-Erik, et al.
Publicado: (2021)

Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
por: Ginsberg, Henry N., et al.
Publicado: (2019)

Familial Hypercholesterolemia Genetic Variations and Long-Term Cardiovascular Outcomes in Patients with Hypercholesterolemia Who Underwent Coronary Angiography
por: Lee, Wen-Jane, et al.
Publicado: (2021)

Black Swan Pandemic and the Risk of Pilot Suicide
por: Vuorio, Alpo, et al.
Publicado: (2020)

Safety of Health Care Workers in a War Zone—A European Issue
por: Vuorio, Alpo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j2t3mbbo1k0n18udi6m9rq5ct1